Management of Adrenocortical Carcinoma

Adrenocortical carcinomas (ACCs) are rare tumors that arise from the cortex of the adrenal gland with an incidence 1 to 2 per million. The rarity of this tumor translates into a paucity of experience in managing patients in most medical centers. Because clinical series are small and prospective evaluation of treatment strategies is limited, the current state of knowledge is strongly influenced by expert consensus opinion from a few medical centers specializing in ACCs. This article describes the basic diagnostic and prognostic issues in adrenal cancer management, and presents detailed rationales for therapeutic management.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Gerard M. Doherty, MD, University of Michigan, 2920 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109. E-mail: gerardd@med.umich.edu

Disclosure: Jonathan R. Strosberg, MD, has disclosed no relevant financial relationships.

Disclosure: Gary D. Hammer, MD, has disclosed no relevant financial relationships.

Disclosure: Gerard M. Doherty, MD, has disclosed no relevant financial relationships.

Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

References

  • 1

    DackiwAPLeeJEGagelRFEvansDB. Adrenal cortical carcinoma. World J Surg2001;25:914926.

  • 2

    AllolioBFassnachtM. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab2006;91:20272037.

  • 3

    NgLLibertinoJM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol2003;169:511.

  • 4

    SchteingartDEDohertyGMGaugerPG. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer2005;12:667680.

    • Search Google Scholar
    • Export Citation
  • 5

    CrucittiFBellantoneRFerranteA. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery1996;119:161170.

    • Search Google Scholar
    • Export Citation
  • 6

    WootenMDKingDK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer1993;72:31453155.

    • Search Google Scholar
    • Export Citation
  • 7

    KochCAPacakKChrousosGP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab2002;87:53675384.

    • Search Google Scholar
    • Export Citation
  • 8

    LynchHTRadfordBLynchJF. SBLA syndrome revisited. Oncology1990;47:7579.

  • 9

    BrandiMLGagelRFAngeliA. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab2001;86:56585671.

  • 10

    MarxSSpiegelAMSkarulisMC. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med1998;129:484494.

  • 11

    SoonPSMcDonaldKLRobinsonBGSidhuSB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist2008;13:548561.

  • 12

    ReinckeMKarlMTravisWH. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab1994;78:790794.

    • Search Google Scholar
    • Export Citation
  • 13

    OhgakiHKleihuesPHeitzPU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer1993;54:408410.

  • 14

    GicquelCBertagnaXSchneidH. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab1994;78:14441453.

    • Search Google Scholar
    • Export Citation
  • 15

    GicquelCRaffin-SansonMLGastonV. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab1997;82:25592565.

    • Search Google Scholar
    • Export Citation
  • 16

    BarlaskarFMHammerGD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord2007;8:343348.

  • 17

    LutonJPCerdasSBillaudL. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med1990;322:11951201.

    • Search Google Scholar
    • Export Citation
  • 18

    BertagnaCOrthDN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med1981;71:855875.

    • Search Google Scholar
    • Export Citation
  • 19

    Kasperlik-ZaluskaAAMigdalskaBMZgliczynskiSMakowskaAM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer1995;75:25872591.

    • Search Google Scholar
    • Export Citation
  • 20

    NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens State Sci Statements2002;19:125.

    • Search Google Scholar
    • Export Citation
  • 21

    KorobkinMLombardiTJAisenAM. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology1995;197:411418.

    • Search Google Scholar
    • Export Citation
  • 22

    YunMKimWAlnafisiN. 18 F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med2001;42:17951799.

  • 23

    CaoiliEMKorobkinMBrownRK. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol2007;14:468475.

    • Search Google Scholar
    • Export Citation
  • 24

    Al-HawaryMMFrancisIRKorobkinM. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab2005;19:277292.

    • Search Google Scholar
    • Export Citation
  • 25

    SzolarDHKorobkinMReittnerP. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT[see comment]. Radiology2005;234:479485.

    • Search Google Scholar
    • Export Citation
  • 26

    HussainHKKorobkinM. MR imaging of the adrenal glands. Magn Reson Imaging Clin N Am2004;12:515544.

  • 27

    IsraelGMKorobkinMWangC. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol2004;183:215219.

    • Search Google Scholar
    • Export Citation
  • 28

    BechererAVierhapperHPotziC. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm2001;16:289295.

  • 29

    LeboulleuxSDromainCBonniaudG. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab2006;91:920925.

    • Search Google Scholar
    • Export Citation
  • 30

    SchultzCLHaagaJRFletcherBD. Magnetic resonance imaging of the adrenal glands: a comparison with computed tomography. AJR Am J Roentgenol1984;143:12351240.

    • Search Google Scholar
    • Export Citation
  • 31

    ChangAGlazerHSLeeJK. Adrenal gland: MR imaging. Radiology1987;163:123128.

  • 32

    WeissLMMedeirosLJVickeryAL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol1989;13:202206.

    • Search Google Scholar
    • Export Citation
  • 33

    AubertSWacrenierALeroyX. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol2002;26:16121619.

    • Search Google Scholar
    • Export Citation
  • 34

    DeLellisRALloydRVHeitzPUEngC eds. World Health Organization Classification of Tumours: Pathology & Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004.

    • Search Google Scholar
    • Export Citation
  • 35

    MacfarlaneDA. Cancer of the adrenal cortex. Ann R Coll Surg1958;23:155186.

  • 36

    WeissLM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol1984;8:163169.

    • Search Google Scholar
    • Export Citation
  • 37

    AssieGAntoniGTissierF. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab2007;92:148154.

  • 38

    IcardPGoudetPCharpenayC. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg2001;25:891897.

    • Search Google Scholar
    • Export Citation
  • 39

    SaundersBDDohertyGM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol2004;5:718726.

  • 40

    DicksteinGShechnerCAradE. Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma?J Clin Endocrinol Metab1998;83:31003103.

    • Search Google Scholar
    • Export Citation
  • 41

    Khorram-ManeshAAhlmanHJanssonS. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg1998;22:605611; discussion 611–612.

    • Search Google Scholar
    • Export Citation
  • 42

    Vassilopoulou-SellinRGuineeVFKleinMJ. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer1993;71:31193123.

    • Search Google Scholar
    • Export Citation
  • 43

    TerzoloMAngeliAFassnachtM. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med2007;356:23722380.

  • 44

    SchteingartDE. Adjuvant mitotane therapy of adrenal cancer—use and controversy[see comment]. N Engl J Med2007;356:24152418.

  • 45

    HaakHRHermansJvan de VeldeCJ. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer1994;69:947951.

    • Search Google Scholar
    • Export Citation
  • 46

    HutterAMJrKayhoeDE. Adrenal cortical carcinoma. Results of treatment with o,p’DDD in 138 patients. Am J Med1966;41:581592.

  • 47

    MageeBJGattamaneniHRPearsonD. Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol1987;38:587588.

  • 48

    PercarpioBKnowltonAH. Radiation therapy of adrenal cortical carcinoma. Acta Rad Ther Phys Biol1976;15:288.

  • 49

    FassnachtMHahnerSPolatB. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma[see comment]. J Clin Endocrinol Metab2006;91:45014504.

    • Search Google Scholar
    • Export Citation
  • 50

    HahnerSFassnachtM. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs2005;6:386394.

  • 51

    LubitzJAFreemanLOkunR. Mitotane use in inoperable adrenal cortical carcinoma. JAMA1973;223:11091112.

  • 52

    VenkateshSHickeyRCSellinRV. Adrenal cortical carcinoma. Cancer1989;64:765769.

  • 53

    BerrutiATerzoloMSperoneP. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer2005;12:657666.

    • Search Google Scholar
    • Export Citation
  • 54

    KhanTSImamHJuhlinC. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol2000;11:12811287.

    • Search Google Scholar
    • Export Citation
  • 55

    KoschkerACFassnachtMHahnerS. Adrenocortical carcinoma—improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes2006;114:4551.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 54 54 12
PDF Downloads 26 26 9
EPUB Downloads 0 0 0